Skinuva Scar Plus
Zinc Oxide
Md Medical Designs, Inc.
Human Otc Drug
NDC 82350-352Skinuva Scar Plus also known as Zinc Oxide is a human otc drug labeled by 'Md Medical Designs, Inc.'. National Drug Code (NDC) number for Skinuva Scar Plus is 82350-352. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Skinuva Scar Plus drug includes Zinc Oxide - .1 g/mL . The currest status of Skinuva Scar Plus drug is Active.
Drug Information:
| Drug NDC: | 82350-352 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Skinuva Scar Plus |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Zinc Oxide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Md Medical Designs, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | ZINC OXIDE - .1 g/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 30 Jun, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 07 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part352 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | MD Medical Designs, Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | SOI2LOH54Z
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 82350-352-15 | 1 BOTTLE in 1 CARTON (82350-352-15) / 15 mL in 1 BOTTLE | 30 Jun, 2022 | N/A | No |
| 82350-352-30 | 1 BOTTLE in 1 CARTON (82350-352-30) / 30 mL in 1 BOTTLE | 30 Jun, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Active ingredients purpose data on file zinc oxide 10% sunscreen dosage form cream
Product Elements:
Skinuva scar plus zinc oxide zinc oxide zinc oxide water dimethicone cyclomethicone 5 butylene glycol glycerin diethylhexyl 2,6-naphthalate dimethicone/peg-10/15 crosspolymer tetrahexyldecyl ascorbate centella asiatica triterpenoids diphenylsiloxy phenyl trimethicone dimethicone/phenyl vinyl dimethicone crosspolymer phenylethyl alcohol ethylhexylglycerin sodium chloride lauryl peg-9 polydimethylsiloxyethyl dimethicone hyaluronate sodium aloe vera leaf basic fibroblast growth factor (human) tocopherol ilodecakin
Indications and Usage:
Uses helps prevent sunburn. if used as directed with other sun protection measures, decreases the risk of skin cancer and early skin aging caused by the sun.
Warnings:
Warnings for external use only. do not use on damaged/broken skin or open wounds. when using this product keep out of eyes. if contact occurs, rinse eyes thoroughly with plenty of water to remove. if swallowed immediately seek medical advice and show container or label. stop use and ask a doctor if rash or irritation occurs. keep out of reach of children.
Do Not Use:
Warnings for external use only. do not use on damaged/broken skin or open wounds. when using this product keep out of eyes. if contact occurs, rinse eyes thoroughly with plenty of water to remove. if swallowed immediately seek medical advice and show container or label. stop use and ask a doctor if rash or irritation occurs. keep out of reach of children.
When Using:
When using this product keep out of eyes. if contact occurs, rinse eyes thoroughly with plenty of water to remove. if swallowed immediately seek medical advice and show container or label.
Dosage and Administration:
Directions make sure the affected area is clean and dry. apply a thin film over the affected area twice a day, morning and night. wait 15 minutes before sun exposure. children under 6 months of age: ask a doctor. see insert for detailed instructions.
Stop Use:
Stop use and ask a doctor if rash or irritation occurs.
Package Label Principal Display Panel:
Principal display panel - 30 ml bottle carton ndc: 82350-352-30 skinuva ® scar+ broad spectrum spf 30 scar photoaging defense cream using highly selective growth factors with zinc oxide mineral sunscreen developed and tested by physicians 30 ml / 1 fl. oz e principal display panel - 30 ml bottle carton